The deal values BioLife at approximately $1.5 billion, with 64% paid in Repligen stock and 36% in cash.
Repligen will acquire BioLife Solutions in a transaction valued at roughly $1.5 billion, structured as 64% stock and 36% cash. The agreement marks a significant consolidation in the bioprocessing sector, combining two key players in cell and gene therapy tools.
BioLife’s enterprise value reflects a premium over its recent trading levels, aligning with sector trends where strategic acquisitions drive growth. The deal follows a period of heightened M&A activity in life sciences, particularly in tools and services supporting advanced therapies.
No immediate market reaction was disclosed, though shares of both companies may see volatility as investors assess the deal’s strategic fit and valuation.